ICO/IARC Information Centre on HPV and Cancer

Uganda
Human Papillomavirus and Related Cancers, Fact Sheet 2023 (2023-03-10)
I. Key data on HPV and HPV-related cancers
Uganda has a population of Figure 1. Comparison of the ten most frequent HPV
13.1 million women ages 15 oncogenic types in Uganda among women with and
years and older who are at risk without cervical lesions
of developing cervical cancer. 16 2.8
Current estimates indicate that 35 1.6
every year 6959 women are
33 0.8
diagnosed with cervical can-

Normal cytology
cer and 4607 die from the dis- 31 0.8

ease. Cervical cancer ranks 18 0.8

as the 1st most frequent can- 6th *
cer among women in Uganda
and the 1st most frequent can- 7th *

cer among women between 15 8th *

and 44 years of age. About 3.6% of women in the general 9th *

population are estimated to harbour cervical HPV-16/18 infec- 10th *
tion at a given time, and 57.0% of invasive cervical cancers
are attributed to HPVs 16 or 18.
1st *

Table 1. Crude incidence rates of HPV-related can- 2nd *

cers 3th *

Low−grade lesions
Male Female
4th *
Cervical cancer - 30.0
5th *
Anal cancer 0.31 0.19
Vulva cancer - 0.53 6th *

Vaginal cancer - 0.16 7th *

Penile cancer 1.53 - 8th *

Oropharyngeal cancer 0.35 0.06 9th *

Oral cavity cancer 1.17 0.53 10th
HPV types

*
Laryngeal cancer 0.82 0.22
1st *

2nd *
Table 2. Burden of cervical cancer
3th *

High−grade lesions
Incidence Mortality
Annual number of new cases/deaths 6959 4607 4th *

Crude rate 30.0 19.9 5th *

Age-standarized rate 56.2 41.4 6th *

Cumulative risk 0-74 years (%) 5.98 4.70 7th *

Ranking of cervical cancer (all years) 1st 1st 8th *
Ranking of cervical cancer (15-44 years) 1st 1st
9th *

10th *

Table 3. Burden of cervical HPV infection Uganda

16 38
No. Tested % (95% CI)
18 19
HPV 16/18 prevalence:
Normal cytology 251 3.6 (1.9-6.7) 45 7.8
Cervical cancer

Low-grade cervical lesions - - 31 2.8

High-grade cervical lesions - - 51 1.6

Cervical cancer 321 57.0 (51.5-62.3) 56 1.2

35 1.2

52 0.9

33 0.6

39 0.3
0% 10% 20% 30% 40% 50%
Prevalence

For data sources and further data on HPV infection in cancer sites other than the cervix, please refer to the specific country full report.
 ICO/IARC Information Centre on HPV and Cancer

Uganda
Human Papillomavirus and Related Cancers, Fact Sheet 2023 (2023-03-10)
II. Complementary data on cervical cancer prevention
Table 4. Factors contributing to cervical cancer (co- Table 7. Cervical screening practices and recom-
factors) mendations
Smoking prevalence (%) [95% UI], women 2.8 [1.8-3.8] Existence of official national rec- Yes
Total fertility rate (live births per women) 5.5 ommendations
Hormonal contraception use (%) 2.74 Starting year of recommendations 2020
HIV prevalence (%) [95% UI] (15-49 years) 7.1 [6.6-7.7] Active invitation to screening No
Screening ages (years), pri- 25-49 (VIA, 3 years);
mary screening test used, and 30-49 (HPV test, Unk
Table 5. Sexual behaviour screening interval or frequency of years)
screenings
MEN
Percentage of 15-year-old who have had sexual 14.0
Figure 2. Estimated coverage of cervical cancer
intercourse
screening in Uganda*
Range of median age at first sexual intercourse 18.4 - 18.8

WOMEN
25-65 30-49
Percentage of 15-year-old who have had sexual 12.0
intercourse 10

Cervical cancer screening

9
Range of median age at first sexual intercourse 16.7 - 17.6 8
10 7
6
coverage (%)
5
Table 6. HPV vaccine introduction 5
Females
HPV vaccination programme Introduced
0
Year of introduction 2015
er

ars n

ars n
ye d i

ye d i
Ev

Year of estimation 2021

t 5 ene

t 3 ene
laSscre

laSscre
HPV coverage – first dose (%) 75
HPV coverage – last dose (%) 44

Males * Estimated coverage and 95% confidence interval in 2019

HPV vaccination programme Not Available/Not

Introduced Contact information:
Year of introduction -
Year of estimation -
ICO/IARC HPV Information Centre
HPV coverage – first dose (%) -
HPV coverage – last dose (%) - Institut Català d’Oncologia
Avda. Gran Via de l’Hospitalet, 199-203
08908 L’Hospitalet de Llobregat (Barcelona, Spain)
info@hpvcentre.net
www.hpvcentre.net

For data sources and further data on HPV infection in cancer sites other than the cervix, please refer to the specific country full report.